Investigational drug · Phase 2
VERVE-102
Also called: LY4636581
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VERVE-102"
First trial start
2026
Sep 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VERVE-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atherosclerosis
- Cardiovascular Disease
- Hypercholesterolemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "VERVE-102" as an intervention, largest first.
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07839936 · 175 participants (planned) · Start Sep 24, 2026 · Primary completion Aug 2028
Drug: VERVE-102; Placebo · For: Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia
Sites: DeSoto, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT06164730 · 85 participants (planned) · Start Apr 30, 2024 · Primary completion Oct 2026
Drug: VERVE-102 · For: Heterozygous Familial Hypercholesterolemia; Premature Coronary Heart Disease
Sites: Dothan, Alabama; Pomona, California; Boca Raton, Florida · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- VERVEߛ102: Nextߛgeneration PCSK9 baseߛediting for durable LDLߛcholesterol reduction.
Tang XL, Hooper AJ, Burnett JR · Expert Opin Investig Drugs 2026
- Proprotein Convertase Subtilisin/Kexin Type 9: From Biology to Therapeutic Targeting in Cardiovascular Disease.
Rizzo R, Daraban BS, Tudorache IF, et al. · Eur J Clin Invest 2026
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
Vafai SB, Täubel J, Ashdown T, et al. · N Engl J Med 2026
- Interim results of the Heart-2 clinical trial testing the safety and efficacy of VERVE-102 therapy.
Martini E · Nat Cardiovasc Res 2026
- VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol.
Hooper AJ, Tang XL, Burnett JR · Expert Opin Investig Drugs 2024
Also in development for Atherosclerosis
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.